BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder

ANAHEIM, CA, April 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Brady Granier, BioCorRx CEO, President, and Director, as well as actor Jeremy Miller, best known for his role as Ben Seaver on the hit TV show Growing Pains, appeared as guests on Varney & Co on Fox Business.  

Mr. Miller discussed his personal experience with alcoholism and how the implant has been “an absolute game changer” after trying other treatments, unsuccessfully.  In discussing the implant, he noted, “Within hours I started noticing the effects, and what you notice is what’s not there – that constant obsessive need, it just kind of vanished. It’s like a light switch turned off for me.”

During the interview, Mr. Granier discussed the advantages of the Company’s sustained release naltrexone implant, including its efficacy, price points and recent meeting with the FDA regarding its plans to submit the implant, named BICX102, for marketing clearance in order to gain wider payor acceptance.

The segment can be viewed online at

Varney & Co. is a daily morning news/talk program hosted by British-American economic and political commentator Stuart Varney on Fox Business on weekdays 9 AM - 12 PM ET. The show includes market coverage, current events coverage, and interviews and commentary with Wall Street experts. 

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing injectable and implantable naltrexone products for potential future regulatory approval. For more information on BICX, visit

Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.

Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304

Primary Logo

Source: BioCorRx Inc